The weekly newsletter Optimizer by Verge’s Victoria Song will pause for the holidays and return January 9th. Retatrutide, a new weight loss drug, is gaining attention on social media despite not being FDA-approved and currently in clinical trials. Influencers promote it as a miracle peptide, often neglecting to mention its unregulated status and risks. Experts suggest the term “GLP-3” mislabels retatrutide’s mechanism, which targets GLP-1, GIP, and glucagon receptors for appetite suppression.
